Minas P Economides1, Moran Amit2, Parag S Mahale3, Jeff J Hosry1, Ying Jiang1, Uddalak Bharadwaj1, Erich M Sturgis2, Harrys A Torres1,4. 1. Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. 4. Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Although an association between hepatitis C virus (HCV) infection and oropharyngeal cancers (OPCs) has been reported, to the authors' knowledge the clinical significance of this epidemiological finding remains unknown. Therefore, the authors analyzed the oncologic outcomes of HCV-infected patients with OPCs. METHODS: In this retrospective cohort study, all patients with OPCs who were seen at The University of Texas MD Anderson Cancer Center between January 2004 and December 2015 were reviewed. HCV infection was defined as detectable HCV RNA in the serum. Five-year overall survival and progression-free survival rates were compared between patients infected with HCV and those not infected. RESULTS: A total of 161 patients were examined. The majority of the patients were white (141 patients; 88%) and male (132 patients; 82%) and had TNM stage III or IV disease (147 patients; 91%). The OPC involved the tonsils (83 patients; 52%), base of the tongue (67patients; 42%), or the soft palate (11 patients; 7%). The median follow-up after an OPC diagnosis was 3 years (range, 1-13 years). HCV-infected patients (25 patients) and HCV-uninfected patients (136 patients) were comparable with regard to smoking and alcohol status. In multivariate analysis, HCV was associated with increased cancer-specific mortality (hazard ratio, 2.15; 95% confidence interval, 1.08-6.85 [P = .02]) and risk of OPC progression (hazard ratio, 5.42; 95% confidence interval, 2.64-11.14 [P = .0008]) independent of age and cirrhosis status. Antivirals were administered after the diagnosis of OPC in 8 of the 25 HCV-infected patients (32%). HCV-infected patients who received antivirals were found to have better 5-year overall survival (70% vs 12%; P = .005) and progression-free survival (72% vs 19%; P = .005) compared with patients who did not. CONCLUSIONS: The early detection of HCV is important in patients with OPC because this infection may affect their oncologic outcomes. Cancer 2018;124:960-5.
BACKGROUND: Although an association between hepatitis C virus (HCV) infection and oropharyngeal cancers (OPCs) has been reported, to the authors' knowledge the clinical significance of this epidemiological finding remains unknown. Therefore, the authors analyzed the oncologic outcomes of HCV-infectedpatients with OPCs. METHODS: In this retrospective cohort study, all patients with OPCs who were seen at The University of Texas MD Anderson Cancer Center between January 2004 and December 2015 were reviewed. HCV infection was defined as detectable HCV RNA in the serum. Five-year overall survival and progression-free survival rates were compared between patients infected with HCV and those not infected. RESULTS: A total of 161 patients were examined. The majority of the patients were white (141 patients; 88%) and male (132 patients; 82%) and had TNM stage III or IV disease (147 patients; 91%). The OPC involved the tonsils (83 patients; 52%), base of the tongue (67patients; 42%), or the soft palate (11 patients; 7%). The median follow-up after an OPC diagnosis was 3 years (range, 1-13 years). HCV-infectedpatients (25 patients) and HCV-uninfectedpatients (136 patients) were comparable with regard to smoking and alcohol status. In multivariate analysis, HCV was associated with increased cancer-specific mortality (hazard ratio, 2.15; 95% confidence interval, 1.08-6.85 [P = .02]) and risk of OPC progression (hazard ratio, 5.42; 95% confidence interval, 2.64-11.14 [P = .0008]) independent of age and cirrhosis status. Antivirals were administered after the diagnosis of OPC in 8 of the 25 HCV-infectedpatients (32%). HCV-infectedpatients who received antivirals were found to have better 5-year overall survival (70% vs 12%; P = .005) and progression-free survival (72% vs 19%; P = .005) compared with patients who did not. CONCLUSIONS: The early detection of HCV is important in patients with OPC because this infection may affect their oncologic outcomes. Cancer 2018;124:960-5.
Authors: Parag Mahale; Eric A Engels; Ruosha Li; Harrys A Torres; Lu-Yu Hwang; Eric L Brown; Jennifer R Kramer Journal: Gut Date: 2017-06-20 Impact factor: 23.059
Authors: Harrys A Torres; Terri Lynn Shigle; Nassim Hammoudi; James T Link; Felipe Samaniego; Ahmed Kaseb; Vincent Mallet Journal: CA Cancer J Clin Date: 2017-07-06 Impact factor: 508.702
Authors: Jason Hunt; Joseph Hagan; James Nobles; Christian Wold; Mary Fazekas-May; Jill Gilbert; Paul L Friedlander Journal: Laryngoscope Date: 2005-10 Impact factor: 3.325
Authors: Jonghun J Lee; Peter T W Kim; Sandra Fischer; Scott Fung; Steven Gallinger; Ian McGilvray; Carol-Anne Moulton; Alice C Wei; Paul D Greig; Sean P Cleary Journal: Ann Surg Oncol Date: 2014-05-08 Impact factor: 5.344
Authors: Carlos A Ramos; Rima M Saliba; Leandro de Pádua; Ola Khorshid; Elizabeth J Shpall; Sergio Giralt; Poliana A Patah; Chitra M Hosing; Uday R Popat; Gabriela Rondon; Issa F Khouri; Yago L Nieto; Richard E Champlin; Marcos de Lima Journal: Haematologica Date: 2009-01-14 Impact factor: 9.941
Authors: Jeff Hosry; Parag Mahale; Francesco Turturro; Roberto N Miranda; Minas P Economides; Bruno P Granwehr; Harrys A Torres Journal: Int J Cancer Date: 2016-08-18 Impact factor: 7.396
Authors: Sven H Loosen; David Schöler; Mark Luedde; Johannes Eschrich; Tom Luedde; Karel Kostev; Christoph Roderburg Journal: J Cancer Res Clin Oncol Date: 2022-07-22 Impact factor: 4.322
Authors: Harrys A Torres; Anna S Lok; Maria E Suarez-Almazor; Carla L Warneke; Ahmed Kaseb; Ethan Miller; Erich M Sturgis; Jessica T Foreman; Georgios Angelidakis; Sairah Ahmed; Alessandra Ferrajoli; Felipe Samaniego; Ernest T Hawk; Jessica P Hwang Journal: Support Care Cancer Date: 2020-04-20 Impact factor: 3.603